

Yohei Doi

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6998654/publications.pdf](https://exaly.com/author-pdf/6998654/publications.pdf)

Version: 2024-02-01

381
papers

25,272
citations

8910

75
h-index

9570

144
g-index

399
all docs

399
docs citations

399
times ranked

25850
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 161-168.	8.9	4,292
2	The global epidemiology of carbapenemase-producing Enterobacteriaceae. <i>Virulence</i> , 2017, 8, 460-469.	4.5	654
3	16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. <i>Clinical Infectious Diseases</i> , 2007, 45, 88-94.	5.7	597
4	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2018, 66, 163-171.	5.7	514
5	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	8.9	484
6	Treatment Outcome of Bacteremia Due to KPC-Producing <i>Klebsiella pneumoniae</i> : Superiority of Combination Antimicrobial Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2108-2113.	3.4	472
7	Colistin and its role in the Era of antibiotic resistance: an extended review (2000â€“2019). <i>Emerging Microbes and Infections</i> , 2020, 9, 868-885.	6.6	402
8	Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. <i>Clinical Infectious Diseases</i> , 2019, 69, S565-S575.	5.7	393
9	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	8.9	379
10	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 1615-1618.	5.7	373
11	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	373
12	Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. <i>New England Journal of Medicine</i> , 2018, 379, 236-249.	30.1	319
13	Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1 -positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 390-399.	8.9	311
14	PCR Typing of Genetic Determinants for Metallo-Î²-Lactamases and Integrases Carried by Gram-Negative Bacteria Isolated in Japan, with Focus on the Class 3 Integron. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5407-5413.	4.4	301
15	Community-Associated Extended-Spectrum Î²-Lactamase-Producing <i>Escherichia coli</i> Infection in the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 641-648.	5.7	281
16	Aminoglycoside Resistance. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 523-537.	4.2	262
17	Natural History of Asymptomatic SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2020, 383, 885-886.	30.1	253
18	<i>Acinetobacter baumannii</i> : Evolution of Antimicrobial Resistanceâ€”Treatment Options. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 085-098.	2.2	243

#	ARTICLE	IF	CITATIONS
19	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.	5.7	234
20	New Treatment Options against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	219
21	Carbapenem-resistant and colistin-resistant <i>Escherichia coli</i> co-producing NDM-9 and MCR-1. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 288-289.	8.9	218
22	Acquisition of 16S rRNA methylase gene in <i>Pseudomonas aeruginosa</i> . <i>Lancet</i> , The, 2003, 362, 1888-1893.	12.1	200
23	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 731-741.	8.9	200
24	The ecology of extended-spectrum β -lactamases (ESBLs) in the developed world. <i>Journal of Travel Medicine</i> , 2017, 24, S44-S51.	3.0	189
25	A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	183
26	Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Infections. <i>Drugs</i> , 2014, 74, 1315-1333.	11.1	181
27	Carbapenemase-Producing Enterobacteriaceae. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 074-084.	2.2	179
28	<i>Pseudomonas aeruginosa</i> utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. <i>Journal of Clinical Investigation</i> , 2018, 128, 4639-4653.	8.2	178
29	Carbapenem-Resistant Enterobacteriaceae. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 303-315.	1.5	171
30	A Primer on AmpC β -Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. <i>Clinical Infectious Diseases</i> , 2019, 69, 1446-1455.	5.7	171
31	Plasmid-Mediated 16S rRNA Methylase in <i>Serratia marcescens</i> Conferring High-Level Resistance to Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 491-496.	3.4	168
32	Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4831-4840.	3.4	168
33	Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens. <i>PLoS ONE</i> , 2013, 8, e63397.	2.5	163
34	CTX-M-15-D-ST648 <i>Escherichia coli</i> from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1224-1230.	3.2	162
35	Colistin Resistance in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Laboratory Detection and Impact on Mortality. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw805.	5.7	153
36	Dissemination of the mcr-1 colistin resistance gene. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 292-293.	8.9	153

#	ARTICLE	IF	CITATIONS
37	Rational Design of Engineered Cationic Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan, and Their Activity against Multidrug-Resistant Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2511-2521.	3.4	152
38	Clinical outcomes and bacterial characteristics of carbapenem-resistant <i>Klebsiella pneumoniae</i> complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. <i>Lancet Infectious Diseases</i> , 2022, 22, 401-412.	8.9	152
39	Normal Development of Mice and Unimpaired Cell Adhesion/Cell Motility/Actin-based Cytoskeleton without Compensatory Up-regulation of Ezrin or Radixin in Moesin Gene Knockout. <i>Journal of Biological Chemistry</i> , 1999, 274, 2315-2321.	3.5	150
40	Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant- <i>Acinetobacter baumannii</i> Infection. <i>PLoS ONE</i> , 2012, 7, e29446.	2.5	150
41	Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal <i>fosA</i> Gene. <i>MBio</i> , 2017, 8, .	4.4	146
42	Practical Methods Using Boronic Acid Compounds for Identification of Class C β -Lactamase-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Journal of Clinical Microbiology</i> , 2005, 43, 2551-2558.	4.4	145
43	Genetic Basis of Multidrug Resistance in <i>Acinetobacter baumannii</i> Clinical Isolates at a Tertiary Medical Center in Pennsylvania. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3837-3843.	3.4	145
44	Extended-spectrum and CMY-type β -lactamase-producing <i>Escherichia coli</i> in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. <i>Clinical Microbiology and Infection</i> , 2010, 16, 33-38.	6.5	135
45	PCR Classification of CTX-M-Type β -Lactamase Genes Identified in Clinically Isolated Gram-Negative Bacilli in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 791-795.	3.4	133
46	Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1569-1577.	3.2	127
47	Global Spread of Multiple Aminoglycoside Resistance Genes. <i>Emerging Infectious Diseases</i> , 2005, 11, 951-953.	4.4	126
48	Colistin-Resistant, <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>Klebsiella pneumoniae</i> Belonging to the International Epidemic Clone ST258. <i>Clinical Infectious Diseases</i> , 2011, 53, 373-376.	5.7	126
49	Possible Transmission of <i>mcr-1</i> "Harboring <i>Escherichia coli</i> between Companion Animals and Human. <i>Emerging Infectious Diseases</i> , 2016, 22, 1679-1681.	4.4	126
50	A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli. <i>Clinical Infectious Diseases</i> , 2007, 45, 1179-1181.	5.7	123
51	Clinical Outcomes of Hospital-Acquired Infection with <i>Acinetobacter nosocomialis</i> and <i>Acinetobacter pittii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4172-4179.	3.4	123
52	Molecular Epidemiology of Carbapenem-Nonsusceptible <i>Acinetobacter baumannii</i> in the United States. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3849-3854.	4.4	122
53	Molecular Epidemiology of CTX-M-Producing <i>Escherichia coli</i> Isolates at a Tertiary Medical Center in Western Pennsylvania. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4733-4739.	3.4	117
54	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2017, 64, S30-S35.	5.7	117

#	ARTICLE	IF	CITATIONS
55	Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1329-1333.	3.4	110
56	Novel Plasmid-Mediated 16S rRNA Methylase, RmtC, Found in a <i>Proteus mirabilis</i> Isolate Demonstrating Extraordinary High-Level Resistance against Various Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 178-184.	3.4	107
57	Proposal for assignment of allele numbers for mobile colistin resistance (<i>mcr</i>) genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2625-2630.	3.2	104
58	Extensively Drug-Resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2009, 15, 980-982.	4.4	102
59	Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 2619-2633.	4.9	100
60	Coproduction of Novel 16S rRNA Methylase RmtD and Metallo- β -Lactamase SPM-1 in a Panresistant <i>Pseudomonas aeruginosa</i> Isolate from Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 852-856.	3.4	99
61	Structural Modification of Lipopolysaccharide Conferred by <i>mcr-1</i> in Gram-Negative ESKAPE Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	98
62	A novel apoptosis-inducing protein from <i>Helicobacter pylori</i> . <i>Molecular Microbiology</i> , 2003, 47, 443-451.	2.5	97
63	<i>Escherichia coli</i> Producing CTX-M-2 β -Lactamase in Cattle, Japan. <i>Emerging Infectious Diseases</i> , 2004, 10, 69-75.	4.4	97
64	Fosfomycin: Resurgence of an old companion. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 273-280.	1.7	97
65	Spectrum of excess mortality due to carbapenem-resistant <i>Klebsiella pneumoniae</i> infections. <i>Clinical Microbiology and Infection</i> , 2016, 22, 513-519.	6.5	97
66	Interspecies Spread of <i>Klebsiella pneumoniae</i> Carbapenemase Gene in a Single Patient. <i>Clinical Infectious Diseases</i> , 2009, 49, 1736-1738.	5.7	95
67	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	2.8	95
68	Emergence of the Plasmid-Mediated <i>mcr-1</i> Gene in Colistin-Resistant <i>Enterobacter aerogenes</i> and <i>Enterobacter cloacae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3862-3863.	3.4	94
69	Mutations of the <i>ompK36</i> Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing <i>Klebsiella pneumoniae</i> Strains to Doripenem and Doripenem-Colistin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5258-5265.	3.4	88
70	Dynamics of <i>mcr-1</i> prevalence and <i>mcr-1</i> -positive <i>Escherichia coli</i> after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing-based molecular epidemiological study. <i>Lancet Microbe</i> , The, 2020, 1, e34-e43.	6.7	88
71	Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. <i>Science Advances</i> , 2020, 6, eaay6817.	10.9	87
72	Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 347-356.	3.1	86

#	ARTICLE	IF	CITATIONS
73	Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in <i>Enterobacter cloacae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2833-2835.	3.4	83
74	Impact Metrics for Social Innovation: Barriers or Bridges to Radical Change?. <i>Journal of Social Entrepreneurship</i> , 2012, 3, 133-150.	2.4	83
75	An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. <i>ACS Infectious Diseases</i> , 2016, 2, 478-488.	4.0	83
76	Coproduction of 16S rRNA Methyltransferase RmtD or RmtG with KPC-2 and CTX-M Group Extended-Spectrum β -Lactamases in <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2397-2400.	3.4	80
77	Genomic Epidemiology of an Endoscope-Associated Outbreak of <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> . <i>PLoS ONE</i> , 2015, 10, e0144310.	2.5	75
78	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 667-671.	5.7	74
79	Detection of plasmid-mediated class C β -lactamases. <i>International Journal of Infectious Diseases</i> , 2007, 11, 191-197.	3.3	71
80	High Rates of Human Fecal Carriage of mcr-1-Positive Multidrug-Resistant Enterobacteriaceae Emerge in China in Association With Successful Plasmid Families. <i>Clinical Infectious Diseases</i> , 2018, 66, 676-685.	5.7	70
81	High prevalence of CTX-M-15-producing <i>Klebsiella pneumoniae</i> among inpatients and outpatients with urinary tract infection in Southern India. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1393-1394.	3.2	69
82	Extended-Spectrum AmpC Cephalosporinase in <i>Acinetobacter baumannii</i> : ADC-56 Confers Resistance to Cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4922-4925.	3.4	69
83	Risk factors and outcome of extended-spectrum β -lactamase-producing <i>Enterobacter cloacae</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 26-32.	3.3	68
84	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant <i>Acinetobacter baumannii</i> : using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 70, 246-252.	1.8	68
85	Emergence of <i>mcr-1</i> in <i>Raoultella ornithinolytica</i> and <i>Escherichia coli</i> Isolates from Retail Vegetables in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	68
86	Identification of the ESKAPE pathogens by mass spectrometric analysis of microbial membrane glycolipids. <i>Scientific Reports</i> , 2017, 7, 6403.	3.4	68
87	Whole-Genome Assembly of <i>Klebsiella pneumoniae</i> Coproducing NDM-1 and OXA-232 Carbapenemases Using Single-Molecule, Real-Time Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5947-5953.	3.4	66
88	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 169, 851-858.	2.7	66
89	Activities of Vancomycin-Containing Regimens against Colistin-Resistant <i>Acinetobacter baumannii</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2103-2108.	3.4	65
90	Nosocomial Spread of Ceftazidime-Resistant <i>Klebsiella pneumoniae</i> Strains Producing a Novel Class A β -Lactamase, GES-3, in a Neonatal Intensive Care Unit in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1960-1967.	3.4	64

#	ARTICLE	IF	CITATIONS
91	Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A β -Lactamase, GES-4, Possessing a Single G170S Substitution in the Ω -Loop. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2905-2910.	3.4	64
92	Identification of 16S rRNA Methylase-Producing <i>Acinetobacter baumannii</i> Clinical Strains in North America. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4209-4210.	3.4	64
93	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by <i>Enterobacter</i> , <i>Citrobacter</i> or <i>Serratia</i> species: a systematic review with meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 296-306.	3.2	64
94	Structural modification of LPS in colistin-resistant, KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3035-3042.	3.2	63
95	<i>mcr-1</i> Harboring <i>Salmonella enterica</i> Serovar Typhimurium Sequence Type 34 in Pigs, China. <i>Emerging Infectious Diseases</i> , 2017, 23, 291-295.	4.4	63
96	Respiratory Microbiome Profiling for Etiologic Diagnosis of Pneumonia in Mechanically Ventilated Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 1413.	3.6	63
97	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 1826-1833.	5.7	63
98	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. <i>Clinical Microbiology and Infection</i> , 2017, 23, 533-541.	6.5	62
99	Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	62
100	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in <i>Enterobacter cloacae</i> Complex Following Exposure to Cefepime. <i>Clinical Infectious Diseases</i> , 2020, 71, 2713-2716.	5.7	61
101	Multiclonal Outbreak of <i>Klebsiella pneumoniae</i> Producing Extended-Spectrum β -Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1790-1793.	3.4	60
102	Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection. <i>International Journal of Infectious Diseases</i> , 2021, 107, 195-200.	3.3	59
103	Co-Production of NDM-1 and OXA-232 by <i>Klebsiella pneumoniae</i> . <i>Emerging Infectious Diseases</i> , 2014, 20, 163-165.	4.4	59
104	Genetic Environments of the <i>rmtA</i> Gene in <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2069-2074.	3.4	57
105	Franchise Partnership and International Expansion: A Conceptual Framework and Research Propositions. <i>Entrepreneurship Theory and Practice</i> , 2011, 35, 533-557.	10.7	57
106	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	57
107	Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. <i>Atherosclerosis</i> , 1997, 132, 145-150.	0.8	55
108	Apoptotic Signaling Pathway Activated by <i>Helicobacter pylori</i> Infection and Increase of Apoptosis-Inducing Activity under Serum-Starved Conditions. <i>Infection and Immunity</i> , 2001, 69, 3181-3189.	2.4	55

#	ARTICLE	IF	CITATIONS
109	Characterization of a Novel Plasmid-Mediated Cephalosporinase (CMY-9) and Its Genetic Environment in an <i>Escherichia coli</i> Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2427-2434.	3.4	54
110	Randomized Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in Acute Migraine Headache. <i>Headache</i> , 2008, 48, 333-340.	3.6	54
111	Aerosolization of <i>Acinetobacter baumannii</i> in a Trauma ICU*. <i>Critical Care Medicine</i> , 2013, 41, 1915-1918.	0.9	53
112	Features of Infections Due to <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>Escherichia coli</i> : Emergence of Sequence Type 131. <i>Clinical Infectious Diseases</i> , 2012, 55, 224-231.	5.7	52
113	Complete Sequence of a Novel IncR-F33:AB Plasmid, pKP1034, Harboring <i>fosA3</i> , <i>bla</i> _{KPC-2} , <i>bla</i> _{CTX-M-65} , <i>bla</i> _{SHV-12} , and <i>rmtB</i> from an Epidemic <i>Klebsiella pneumoniae</i> Sequence Type 11 Strain in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1343-1348.	3.4	52
114	Novel 16S rRNA Methyltransferase RmTH Produced by <i>Klebsiella pneumoniae</i> Associated with War-Related Trauma. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2413-2416.	3.4	51
115	Glutathione-S-transferase FosA6 of <i>Klebsiella pneumoniae</i> origin conferring fosfomycin resistance in ESBL-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2460-2465.	3.2	51
116	Antimicrobial treatment challenges in the era of carbapenem resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 413-425.	1.8	51
117	High Prevalence of Metallo- β -Lactamase and 16S rRNA Methylase Coproduction among Imipenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3388-3390.	3.4	48
118	MCR-1-producing <i>Klebsiella pneumoniae</i> outbreak in China. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 577.	8.9	48
119	TNF- α and INF- γ primed canine stem cell-derived extracellular vesicles alleviate experimental murine colitis. <i>Scientific Reports</i> , 2020, 10, 2115.	3.4	47
120	Clinical Features and Molecular Epidemiology of CMY-type β -Lactamase-Producing <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2009, 48, 739-744.	5.7	46
121	Fosfomycin Resistance in <i>Escherichia coli</i> , Pennsylvania, USA. <i>Emerging Infectious Diseases</i> , 2015, 21, 2045-2047.	4.4	46
122	The Rise of Fluoroquinolone-Resistant <i>Escherichia coli</i> in the Community: Scarier Than We Thought. <i>Journal of Infectious Diseases</i> , 2015, 212, 1853-1855.	3.9	46
123	Characterization of a Naturally Occurring Class D β -Lactamase from <i>Achromobacter xylosoxidans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1952-1956.	3.4	45
124	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.7	45
125	Spread of Novel Aminoglycoside Resistance Gene <i>aac</i> (6- Iad) among <i>Acinetobacter</i> Clinical Isolates in Japan. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2075-2080.	3.4	44
126	Characterisation of clinical and food animal <i>Escherichia coli</i> isolates producing CTX-M-15 extended-spectrum β -lactamase belonging to ST410 phylogroup A. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 365-367.	3.3	44

#	ARTICLE	IF	CITATIONS
127	Risk factors for acquisition of multidrug-resistant <i>Acinetobacter baumannii</i> among cancer patients. <i>American Journal of Infection Control</i> , 2013, 41, 1249-1252.	2.5	44
128	<i>Klebsiella pneumoniae</i> ST147 Coproducing NDM-7 Carbapenemase and RmtF 16S rRNA Methyltransferase in Minnesota. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4109-4110.	4.4	44
129	Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz353.	0.9	44
130	Inhibitor-Sensitive AmpC β -Lactamase Variant Produced by an <i>Escherichia coli</i> Clinical Isolate Resistant to Oxyiminocephalosporins and Cephamycins. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2652-2658.	3.4	43
131	Enhancing Resistance to Cephalosporins in Class C β -Lactamases: Impact of Gly214Glu in CMY-2. <i>Biochemistry</i> , 2010, 49, 1014-1023.	2.6	43
132	Activity of Temocillin against KPC-Producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2700-2701.	3.4	42
133	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.2	42
134	Phylogenomics of colistin-susceptible and resistant XDR <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2952-2959.	3.2	42
135	The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates in an endemic setting. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 34-38.	1.8	41
136	In Vitro Responses of <i>Acinetobacter baumannii</i> to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1195-1199.	3.4	41
137	Rapid Microbial Identification and Antibiotic Resistance Detection by Mass Spectrometric Analysis of Membrane Lipids. <i>Analytical Chemistry</i> , 2019, 91, 1286-1294.	6.8	41
138	Community-acquired Extended-Spectrum β -Lactamase Producers, United States. <i>Emerging Infectious Diseases</i> , 2007, 13, 1121-1123.	4.4	40
139	Aminoglycoside Resistance. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 887-902.	4.2	40
140	Identification of Diverse OXA-40 Group Carbapenemases, Including a Novel Variant, OXA-160, from <i>Acinetobacter baumannii</i> in Pennsylvania. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 429-432.	3.4	39
141	Screening for <i>Acinetobacter baumannii</i> Colonization by Use of Sponges. <i>Journal of Clinical Microbiology</i> , 2011, 49, 154-158.	4.4	39
142	Complete Nucleotide Sequences of bla _{CTX-M} -Harboring IncF Plasmids from Community-Associated <i>Escherichia coli</i> Strains in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3002-3007.	3.4	39
143	Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing <i>Klebsiella pneumoniae</i> : Are We at the End of the Road?. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3116-3117.	4.4	39
144	Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7355-7361.	3.4	39

#	ARTICLE	IF	CITATIONS
145	Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> and the Role of TEM-1 Hyperproduction. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 495-501.	3.4	38
146	Clinical characteristics of bacteraemia caused by extended-spectrum β -lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β -lactamases. <i>Clinical Microbiology and Infection</i> , 2012, 18, 887-893.	6.5	38
147	Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 154-158.	1.8	38
148	<i>Acinetobacter baumannii</i> : Association between Environmental Contamination of Patient Rooms and Occupant Status. <i>Infection Control and Hospital Epidemiology</i> , 2013, 34, 517-520.	2.0	37
149	Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. <i>Scientific Reports</i> , 2017, 7, 18098.	3.4	37
150	Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. <i>Frontiers in Microbiology</i> , 2018, 9, 721.	3.6	37
151	Carbapenem-Resistant <i>Acinetobacter baumannii</i> in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. <i>MBio</i> , 2022, 13, e0275921.	4.4	37
152	Molecular Epidemiology of KPC-Producing <i>Escherichia coli</i> : Occurrence of ST131- <i>fimH30</i> Subclone Harboring pKpQIL-Like IncFIIk Plasmid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4234-4237.	3.4	36
153	Coproduction of MCR-1 and NDM-1 by Colistin-Resistant <i>Escherichia coli</i> Isolated from a Healthy Individual. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	36
154	Susceptibility of colistin-resistant pathogens to predatory bacteria. <i>Research in Microbiology</i> , 2018, 169, 52-55.	2.2	36
155	Reed-Sternberg cells in Hodgkin's cell lines HDLM, L-428, and KM-H2 are not actively replicating: lack of bromodeoxyuridine uptake by multinuclear cells in culture. <i>Blood</i> , 1988, 71, 1382-1389.	1.4	35
156	Clinical characteristics and outcomes of community and hospital-acquired <i>Acinetobacter baumannii</i> bacteremia. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 796-806.	3.1	35
157	Carbapenem-Resistant <i>Acinetobacter baumannii</i> : Concomitant Contamination of Air and Environmental Surfaces. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 777-781.	2.0	34
158	Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of <i>Escherichia coli</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	4.4	34
159	Diversity among blaKPC-containing plasmids in <i>Escherichia coli</i> and other bacterial species isolated from the same patients. <i>Scientific Reports</i> , 2018, 8, 10291.	3.4	34
160	<i>In Vitro</i> Evolution of Cefiderocol Resistance in an NDM-Producing <i>Klebsiella pneumoniae</i> Due to Functional Loss of CirA. <i>Microbiology Spectrum</i> , 2021, 9, e0177921.	3.0	34
161	Nomenclature of Plasmid-Mediated 16S rRNA Methylases Responsible for Panaminoglycoside Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2287-2288.	3.4	33
162	CTX-M- β -Lactamase-Producing <i>Salmonella</i> Typhimurium Isolated from Pediatric Patients and Poultry in Brazil. <i>Microbial Drug Resistance</i> , 2009, 15, 317-321.	2.0	33

#	ARTICLE	IF	CITATIONS
163	<i>Bordetella pertussis</i> Clones Identified by Multilocus Variable-Number Tandem-Repeat Analysis. <i>Emerging Infectious Diseases</i> , 2010, 16, 297-300.	4.4	33
164	Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteriuria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3100-3104.	3.4	32
165	Comparative analysis of an IncR plasmid carrying <i>armA</i> , <i>bla</i> _{DHA-1} and <i>qnrB4</i> from <i>Klebsiella pneumoniae</i> ST37 isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 882-886.	3.2	32
166	Clinical and Microbiologic Characteristics of Cephalosporin-Resistant <i>Escherichia coli</i> at Three Centers in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1870-1876.	3.4	31
167	Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Antibiotics</i> , 2016, 69, 415-421.	2.1	30
168	Reduced Susceptibility to Cefepime among <i>Escherichia coli</i> Clinical Isolates Producing Novel Variants of CMY-2 β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3159-3161.	3.4	29
169	CD36 Provides Host Protection Against <i>Klebsiella pneumoniae</i> Intrapulmonary Infection by Enhancing Lipopolysaccharide Responsiveness and Macrophage Phagocytosis. <i>Journal of Infectious Diseases</i> , 2016, 214, 1865-1875.	3.9	29
170	Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	28
171	Detection of high-risk carbapenem-resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i> isolates using volatile molecular profiles. <i>Scientific Reports</i> , 2018, 8, 13297.	3.4	28
172	Origin of the plasmid-mediated fosfomycin resistance gene fosA3. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 373-376.	3.2	27
173	Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant <i>acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 646-650.	3.3	27
174	<i>Escherichia coli</i> Isolate Coproducing 16S rRNA Methylase and CTX-M-Type Extended-Spectrum β -Lactamase Isolated from an Outpatient in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1204-1205.	3.4	26
175	Aliphatic Halogenase Enables Late-Stage C-H Functionalization: Selective Synthesis of a Brominated Fischerindole Alkaloid with Enhanced Antibacterial Activity. <i>ChemBioChem</i> , 2016, 17, 466-470.	2.8	26
176	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114856.	1.8	26
177	“Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens “ The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study“. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 3607-3623.	2.8	26
178	Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab616.	0.9	26
179	PME-1, an Extended-Spectrum β -Lactamase Identified in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2710-2713.	3.4	24
180	Quasiconvexity and relatively hyperbolic groups that split. <i>Michigan Mathematical Journal</i> , 2013, 62, .	0.4	24

#	ARTICLE	IF	CITATIONS
181	Hospital Readmissions in Patients With Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 281-288.	2.0	24
182	High-Level Fosfomycin Resistance in Vancomycin-Resistant <i>Enterococcus faecium</i> . <i>Emerging Infectious Diseases</i> , 2017, 23, 1902-1904.	4.4	24
183	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible <i>Citrobacter</i> spp. at a Tertiary Health Care Center over 2 Decades. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	4.4	24
184	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1779-1785.	3.1	24
185	The CDKN2A and MAP Kinase Pathways. <i>American Journal of Dermatopathology</i> , 2013, 35, 167-175.	0.6	23
186	Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5749-5753.	3.1	22
187	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx157.	0.9	22
188	A Prospective Study of <i>Acinetobacter baumannii</i> Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	4.4	22
189	The Bartonella autotransporter BafA activates the host VEGF pathway to drive angiogenesis. <i>Nature Communications</i> , 2020, 11, 3571.	13.2	22
190	Treatment of carbapenem-resistant <i>Pseudomonas aeruginosa</i> infections: a case for ceftiderocol. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1077-1094.	4.5	22
191	Prenatal development of the agouti (<i>Dasyprocta prymnolopha</i> Wagler, 1831): External features and growth curves. <i>Animal Reproduction Science</i> , 2013, 140, 195-205.	1.6	21
192	Safety and Efficacy of Long-Term Outpatient Ertapenem Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3437-3440.	3.4	21
193	KPC Type B-Lactamase, Rural Pennsylvania. <i>Emerging Infectious Diseases</i> , 2006, 12, 1613-1614.	4.4	20
194	Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. <i>European Radiology</i> , 2018, 28, 5221-5230.	4.6	20
195	Contribution of the TetB Efflux Pump to Minocycline Susceptibility among Carbapenem-Resistant <i>Acinetobacter baumannii</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	20
196	Increase in number of Weibel-Palade bodies and endothelin-1 release from endothelial cells in the cadmium-treated rat thoracic aorta. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1996, 428, 367-73.	2.9	19
197	Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.4	19
198	Prevalence of Extended-Spectrum β -Lactamases CTX-M-8 and CTX-M-2-Producing <i>Salmonella</i> Serotypes from Clinical and Nonhuman Isolates in Brazil. <i>Microbial Drug Resistance</i> , 2017, 23, 580-589.	2.0	19

#	ARTICLE	IF	CITATIONS
199	Use of online tools for antimicrobial resistance prediction by whole-genome sequencing in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and vancomycin-resistant enterococci (VRE). <i>Journal of Global Antimicrobial Resistance</i> , 2019, 19, 136-143.	2.5	19
200	The association of IL-17A polymorphisms with IL-17A serum levels and risk of ischemic stroke. <i>Oncotarget</i> , 2017, 8, 103499-103508.	2.1	19
201	CTX-M as the predominant extended-spectrum β -lactamases among Enterobacteriaceae in Manila, Philippines. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 584-586.	3.2	18
202	Economic Impact of <i>Acinetobacter baumannii</i> Infection in the Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 1087-1089.	2.0	18
203	Sequence Type ST405 <i>Escherichia coli</i> isolate Producing QepA1, CTX-M-15, and RmtB from Detroit, Michigan. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3966-3967.	3.4	18
204	<i>In Vivo</i> Evolution of CMY-2 to CMY-33 β -Lactamase in <i>Escherichia coli</i> Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7483-7488.	3.4	18
205	Carotenoid Pigments in Tubers of the Katahdin Variety of Irish Potato. <i>Plant Physiology</i> , 1947, 22, 421-437.	5.1	17
206	Histamine release from Weibel-Palade bodies of toad aortas induced by endothelin-1 and sarafotoxin-S6b. <i>The Anatomical Record</i> , 1995, 242, 374-382.	1.6	17
207	Congenital malformation of the feet with low body height. <i>Clinical Genetics</i> , 1977, 12, 255-262.	2.2	17
208	Lack of Seasonality in the Occurrence of Multidrug-Resistant <i>Acinetobacter baumannii</i> Complex. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 1051-1052.	2.0	17
209	Elastase Activity From <i>Pseudomonas aeruginosa</i> Respiratory Isolates and ICU Mortality. <i>Chest</i> , 2021, 160, 1624-1633.	0.9	17
210	<i>Escherichia coli</i> sequence type 131: epidemiology and challenges in treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 597-609.	4.5	16
211	Complete Sequence of a Conjugative IncN Plasmid Harboring blaKPC-2, blaSHV-12, and qnrS1 from an <i>Escherichia coli</i> Sequence Type 648 Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6974-6977.	3.4	16
212	Complete Sequence of Conjugative IncA/C Plasmid Encoding CMY-2 β -Lactamase and RmtE 16S rRNA Methyltransferase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4360-4361.	3.4	16
213	OXA-48-Producing Enterobacteriaceae Causing Bacteremia, United Arab Emirates. <i>International Journal of Infectious Diseases</i> , 2015, 30, 36-37.	3.3	16
214	MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria. <i>Emerging Microbes and Infections</i> , 2022, 11, 1236-1249.	6.6	16
215	Genetic Environment of 16S rRNA Methylase Gene <i>rmtD</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2270-2272.	3.4	15
216	Dimensions of stable sets and scrambled sets in positive finite entropy systems. <i>Ergodic Theory and Dynamical Systems</i> , 2012, 32, 599-628.	0.7	15

#	ARTICLE	IF	CITATIONS
217	Penicillins and β -Lactamase Inhibitors. , 2015, , 263-277.e3.		15
218	New Delhi Metallo- β -Lactamase-1 β -Producing <i>Klebsiella pneumoniae</i> , Florida, USA1. Emerging Infectious Diseases, 2016, 22, 744-746.	4.4	15
219	Differential effect of cholesterol on type I and II feline coronavirus infection. Archives of Virology, 2016, 161, 125-133.	1.9	15
220	Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage. Infection Control and Hospital Epidemiology, 2017, 38, 356-359.	2.0	15
221	Emergence of CMY-2-Producing <i>Salmonella</i> Heidelberg Associated with IncI1 Plasmids Isolated from Poultry in Brazil. Microbial Drug Resistance, 2019, 25, 271-276.	2.0	15
222	Moesin Is Not a Receptor for Measles Virus Entry into Mouse Embryonic Stem Cells. Journal of Virology, 1998, 72, 1586-1592.	3.5	15
223	IncX2 and IncX1-X2 Hybrid Plasmids Coexisting in a FosA6-Producing <i>Escherichia coli</i> Strain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.4	14
224	Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of <i>Enterococcus faecalis</i> Infective Endocarditis: A Propensity Score-Matched, Retrospective Cohort Analysis. Open Forum Infectious Diseases, 2021, 8, ofab102.	0.9	14
225	Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus. Clinical Infectious Diseases, 2022, 74, 2067-2076.	5.7	14
226	16S ribosomal RNA methylase RmtD produced by <i>Klebsiella pneumoniae</i> in Brazil. Journal of Antimicrobial Chemotherapy, 2008, 61, 746-747.	3.2	13
227	Economic value of <i>Acinetobacter baumannii</i> screening in the intensive care unit. Clinical Microbiology and Infection, 2011, 17, 1691-1697.	6.5	13
228	<i>Escherichia coli</i> Sequence Type 354 Coproducing CMY-2 Cephalosporinase and RmtE 16S rRNA Methyltransferase. Antimicrobial Agents and Chemotherapy, 2014, 58, 4246-4247.	3.4	13
229	<i>Clostridioides difficile</i> : a potential source of NpmA in the clinical environment. Journal of Antimicrobial Chemotherapy, 2019, 74, 521-523.	3.2	13
230	Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of <i>Citrobacter koseri</i> . Antimicrobial Agents and Chemotherapy, 2021, 65, e0015021.	3.4	13
231	Functional and Structural Characterization of Acquired 16S rRNA Methyltransferase NpmB1 Conferring Pan-Aminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0100921.	3.4	13
232	A Novel Lipid-Based MALDI-TOF Assay for the Rapid Detection of Colistin-Resistant <i>Enterobacter</i> Species. Microbiology Spectrum, 2022, 10, e0144521.	3.0	13
233	Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. Japanese Journal of Radiology, 2022, 40, 800-813.	2.5	13
234	Characterization of a Novel IncHI2 Plasmid Carrying Tandem Copies of <i>bla</i> _{CTX-M-2} in a <i>fosA6</i> -Harboring <i>Escherichia coli</i> Sequence Type 410 Strain. Antimicrobial Agents and Chemotherapy, 2016, 60, 6742-6747.	3.4	12

#	ARTICLE	IF	CITATIONS
235	Coproduction of KPC-18 and VIM-1 Carbapenemases by <i>Enterobacter cloacae</i> : Implications for Newer β -Lactamase Inhibitor Combinations. <i>Journal of Clinical Microbiology</i> , 2016, 54, 791-794.	4.4	12
236	CXC Chemokines Exhibit Bactericidal Activity against Multidrug-Resistant Gram-Negative Pathogens. <i>MBio</i> , 2017, 8, .	4.4	12
237	High-Level Carbapenem Resistance in OXA-232-Producing <i>Raoultella ornithinolytica</i> Triggered by Ertapenem Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.4	12
238	Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 681-686.	1.7	12
239	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy351.	0.9	12
240	A New TEM-Derived Extended-Spectrum β -Lactamase (TEM-91) with an R164C Substitution at the Ω -Loop Confers Ceftazidime Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2981-2983.	3.4	11
241	Biodegradable dextran vesicles for effective haemoglobin encapsulation. <i>Journal of Materials Chemistry B</i> , 2015, 3, 5753-5759.	5.9	11
242	Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Journal of Clinical Microbiology</i> , 2016, 54, 2937-2941.	4.4	11
243	Diversity of High-Level Aminoglycoside Resistance Mechanisms among Gram-Negative Nosocomial Pathogens in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.4	11
244	Evolution of Sequence Type 4821 Clonal Complex Meningococcal Strains in China from Prequinolone to Quinolone Era, 1972-2013. <i>Emerging Infectious Diseases</i> , 2018, 24, 683-690.	4.4	11
245	Small-Molecule Inhibitor of FosA Expands Fosfomicin Activity to Multidrug-Resistant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	11
246	ORF-based binarized structure network analysis of plasmids (OSNAp), a novel approach to core gene-independent plasmid phylogeny. <i>Plasmid</i> , 2020, 108, 102477.	1.4	11
247	The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1689.	6.8	11
248	Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106451.	3.3	11
249	Expression of β -calcitonin gene-related peptide in the enteric nervous system of rat small intestine. <i>Neuroscience Letters</i> , 2000, 285, 33-36.	2.1	10
250	<i>Escherichia coli</i> Producing CMY-2 β -Lactamase in Retail Chicken, Pittsburgh, Pennsylvania, USA. <i>Emerging Infectious Diseases</i> , 2012, 18, 515-516.	4.4	10
251	<i>Klebsiella pneumoniae</i> Sequence Type 11 Isolate Producing RmtG 16S rRNA Methyltransferase from a Patient in Miami, Florida. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4980-4981.	3.4	10
252	Comment on: Resistance gene naming and numbering: is it a new gene or not?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2677-2678.	3.2	10

#	ARTICLE	IF	CITATIONS
253	Molecular epidemiology and spatiotemporal analysis of hospital-acquired <i>Acinetobacter baumannii</i> infection in a tertiary care hospital in southern Thailand. <i>Journal of Hospital Infection</i> , 2017, 95, 53-58.	3.1	10
254	Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection. <i>BMC Emergency Medicine</i> , 2017, 17, 25.	2.0	10
255	Genomic patterns and characterizations of chromosomally-encoded <i>mcr-1</i> in <i>Escherichia coli</i> populations. <i>Gut Pathogens</i> , 2020, 12, 55.	3.9	10
256	Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β -lactamase-producing <i>Escherichia coli</i> . <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1602-1606.	1.7	10
257	Complete Sequences of Multidrug Resistance Plasmids Bearing <i>rmtD1</i> and <i>rmtD216S</i> rRNA Methyltransferase Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1928-1931.	3.4	9
258	OXA-23 and OXA-40 producing carbapenem-resistant <i>Acinetobacter baumannii</i> in Central Illinois. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 114999.	1.8	9
259	Rapid diagnostic testing for antimicrobial stewardship: Utility in Asia Pacific. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 864-868.	2.0	9
260	Other β -Lactam Antibiotics. , 2015, , 293-297.e2.		9
261	Favipiravir for symptomatic COVID-19: A nationwide observational cohort study. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 150-156.	1.7	9
262	Genomic Epidemiology of Carbapenem-Resistant <i>Klebsiella</i> in Qatar: Emergence and Dissemination of Hypervirulent <i>Klebsiella pneumoniae</i> Sequence Type 383 Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	3.4	9
263	Carbonic Anhydrase Inhibition as a Target for Antibiotic Synergy in Enterococci. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	9
264	Molecular Features of Community-Associated Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> Strains in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6953-6957.	3.4	8
265	Comparative Genome Analysis of Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> Sequence Type 131 Strains from Nepal and Japan. <i>MSphere</i> , 2016, 1, .	3.1	8
266	Initial-state splitting kernels in cold nuclear matter. <i>Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics</i> , 2016, 760, 706-712.	4.1	8
267	Effects of Quantum Spin-1/2 Impurities on the Magnetic Properties of Zigzag Spin Chains. <i>Physical Review Letters</i> , 2017, 118, 107201.	8.0	8
268	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	3.3	8
269	Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1075-1087.	4.1	8
270	Vasocontractions of the in-vitro toad aortas induced by endothelin-1 and sarafotoxin-S6b. <i>The Anatomical Record</i> , 1993, 235, 253-260.	1.6	7

#	ARTICLE	IF	CITATIONS
271	Chromosomal 16S Ribosomal RNA Methyltransferase RmtE1 in <i>Escherichia coli</i> Sequence Type 448. <i>Emerging Infectious Diseases</i> , 2000, 23, 876-878.	4.4	7
272	Occurrence of gravid <i>Loa loa</i> in subconjunctival space of man: a case report from West Bengal, India. <i>Journal of Parasitic Diseases</i> , 2012, 37, 52-5.	1.1	7
273	Faropenem Disks for Screening of <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacteriaceae: TABLE 1. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3501-3502.	4.4	7
274	Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization Using Sponges. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 28-33.	2.0	7
275	Carriage of β -lactamase-producing Enterobacteriaceae by Chinese travellers. <i>Lancet Infectious Diseases</i> , 2017, 17, 138-139.	8.9	7
276	Polymyxin Resistance in <i>Klebsiella pneumoniae</i> : Complexity at Every Level. <i>Clinical Infectious Diseases</i> , 2020, 70, 2092-2094.	5.7	7
277	Antibacterial Resistance Leadership Group 2.0: Back to Business. <i>Clinical Infectious Diseases</i> , 2021, 73, 730-739.	5.7	7
278	Fetal and maternal inflammatory response in the setting of maternal intrapartum fever with and without clinical and histologic chorioamnionitis. <i>American Journal of Obstetrics & Gynecology</i> , 2022, 4, 100539.	2.5	7
279	Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2022, 115, 218-223.	3.3	7
280	Transmission of NDM-5-Producing and OXA-48-Producing <i>Escherichia coli</i> Sequence Type 648 by International Visitors without Previous Medical Exposure. <i>Microbiology Spectrum</i> , 2021, 9, e0182721.	3.0	7
281	Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	7
282	Early initiation of three-drug combinations for the treatment of carbapenem-resistant <i>A. baumannii</i> among COVID-19 patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1034-1040.	3.2	7
283	Structure of AmpC β -lactamase (AmpCD) from an <i>Escherichia coli</i> clinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 540-543.	0.7	6
284	Optimal Therapy for Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2010, 16, 171-171.	4.4	6
285	In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, <i>Acinetobacter baumannii</i> , <i>Stenotrophomonas maltophilia</i> , Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013-2015). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	6
286	Disposable Bronchoscope Model for Simulating Endoscopic Reprocessing and Surveillance Cultures. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 136-142.	2.0	6
287	Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx216.	0.9	6
288	Effect of withholding feeds on transfusion-related acute gut injury in preterm infants: a pilot randomized controlled trial. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 4139-4144.	1.7	6

#	ARTICLE	IF	CITATIONS
289	CHARACTERIZATION OF KLEBSIELLA PNEUMONIAE AND ESCHERICHIA COLI STRAINS THAT PRODUCE CTX-M-2-TYPE BROAD SPECTRUM BETA-LACTAMASE ISOLATED FROM A CHILD WITH LEUKEMIA. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 260-262.	2.0	6
290	Delayed Injection Site Reaction After mRNA-1273 Vaccination in Japan: A Retrospective, Cross-Sectional Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab497.	0.9	6
291	Prediction of Antibiotic Resistance Evolution by Growth Measurement of All Proximal Mutants of Beta-Lactamase. <i>Molecular Biology and Evolution</i> , 2022, 39, .	9.2	6
292	High-level ceftazidime/avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated β -lactamase CMY-185 variant. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 2442-2450.	3.2	6
293	Clinical evaluation of a new hearing aid anti-cardioid directivity pattern. <i>International Journal of Audiology</i> , 2011, 50, 249-254.	2.1	5
294	Pharmacokinetic interaction study of combining imatinib with dasatinib in rats by UPLC-MS/MS. <i>Drug Development and Industrial Pharmacy</i> , 2015, 41, 1948-1953.	2.1	5
295	<i>In Vitro</i> Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Clinical Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5101-5101.	3.4	5
296	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in <i>Klebsiella pneumoniae</i> ST258. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2203-2208.	3.2	5
297	Plasmid Carrying bla CTX-M-2 and bla GES-1 in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> from Cerebrospinal Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	5
298	Use of a cohorting-unit and systematic surveillance cultures to control a <i>Klebsiella pneumoniae</i> carbapenemase (KPC)-producing Enterobacteriaceae outbreak. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 767-773.	2.0	5
299	Left ventricular assist device-associated endocarditis involving multiple clones of <i>Staphylococcus aureus</i> with distinct antimicrobial susceptibility patterns. <i>International Journal of Infectious Diseases</i> , 2019, 84, 44-47.	3.3	5
300	A Multiport Solar-assisted SRM Drive for HEV Applications. , 2019, , .		5
301	Phase III Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2353-2369.	4.1	5
302	Rational Framework for the Design of Trp- and Arg-Rich Peptide Antibiotics Against Multidrug-Resistant Bacteria. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.6	5
303	<i>In vitro</i> activity of cefiderocol against <i>Pseudomonas aeruginosa</i> demonstrating evolved resistance to novel β -lactam/ β -lactamase inhibitors. <i>JAC-Antimicrobial Resistance</i> , 2023, 5, .	2.1	5
304	CTX-M-35 extended-spectrum β -lactamase conferring ceftazidime resistance in <i>Citrobacter koseri</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 412-413.	3.3	4
305	Caching Optimization for D2D-Assisted Heterogeneous Wireless Networks. , 2019, , .		4
306	In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β -Lactamase in an <i>Escherichia coli</i> Clinical Isolate Conferring Resistance to Mecillinam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	4

#	ARTICLE	IF	CITATIONS
307	Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1255-1264.	2.8	4
308	Duration of carbapenemase-producing Enterobacterales carriage among ICU patients in Miami, FL: A retrospective cohort study. <i>American Journal of Infection Control</i> , 2021, 49, 1281-1286.	2.5	4
309	Epidemiology of carbapenem-resistant Enterobacteriaceae in hospitals of a large healthcare system in Miami, Florida from 2012 to 2016: Five years of experience with an internal registry. <i>American Journal of Infection Control</i> , 2020, 48, 1341-1347.	2.5	4
310	Natural History of Multidrug-Resistant <i>Acinetobacter baumannii</i> Carriage in Intensive Care Units. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 642-643.	2.0	4
311	Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac005.	2.1	4
312	The Passenger Domain of Bartonella bacilliformis BafA Promotes Endothelial Cell Angiogenesis via the VEGF Receptor Signaling Pathway. <i>MSphere</i> , 2022, 7, e0008122.	3.1	4
313	Short-course remdesivir for healthcare-associated COVID-19: Case series from a non-acute care hospital. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 95-97.	1.7	4
314	A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	4
315	Periprosthetic joint infection due to <i>Mycoplasma hominis</i> in a multiple sclerosis patient treated with fingolimod. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1672-1676.	1.7	4
316	IMP-1 type Metallo- β -lactamase Producing <i>Serratia marcescens</i> Strains Isolated from Blood Culture between 1991 to 2000. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2002, 76, 246-253.	0.0	3
317	<i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacteriaceae, Northeast Florida. <i>Southern Medical Journal</i> , 2009, 102, 680-687.	0.7	3
318	Clonal Distribution of Invasive Pneumococci, Czech Republic, 1996–2003. <i>Emerging Infectious Diseases</i> , 2010, 16, 287-289.	4.4	3
319	In Vitro Global Surveillance of Eravacycline and Comparators Against <i>Staphylococcus</i> spp. and <i>Enterococcus</i> spp. Over a 3-Year Period (2013–2015). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	3
320	Evaluation of the Accelerate Pheno System for Identification of <i>Acinetobacter</i> Clinical Isolates and Minocycline Susceptibility Testing. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	4.4	3
321	Insights on Coronavirus Disease 2019 Epidemiology From a Historic Cruise Ship Quarantine. <i>Clinical Infectious Diseases</i> , 2021, 72, e458-e459.	5.7	3
322	Comparison of sCIM and Other Phenotypic Detection Methods for Carbapenemase-Producing <i>Enterobacterales</i> . <i>Microbiology Spectrum</i> , 2021, 9, e0160821.	3.0	3
323	Development of Knowledge-Based Engineering System for Structural Size Optimization of External Fixation Device. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 10775.	2.6	3
324	Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β -Lactamase-Producing <i>Enterobacterales</i> in Patients with Invasive Urinary Tract Infection Considering Renal Function. <i>Antibiotics</i> , 2022, 11, 456.	3.8	3

#	ARTICLE	IF	CITATIONS
325	<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2024, 68, .	3.4	3
326	A possible model: Photothermal excitation via an excited state in the Si:Pd level. <i>Journal of Applied Physics</i> , 1988, 64, 5266-5269.	2.3	2
327	Reply to Falagas and Karageorgopoulos. <i>Clinical Infectious Diseases</i> , 2008, 46, 1122-1123.	5.7	2
328	Fast Appraisal And Development Of A Stratigraphic Carbonate Play. , 2009, , .		2
329	Ceftazidime-avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the USA: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2). <i>Open Forum Infectious Diseases</i> , 2017, 4, S133-S134.	0.9	2
330	Draft Genome Sequences of bla KPC -Containing <i>Enterobacter aerogenes</i> , <i>Citrobacter freundii</i> , and <i>Citrobacter koseri</i> Strains. <i>Genome Announcements</i> , 2018, 6, .	0.8	2
331	636. Genome Epidemiology of Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAb) in the United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, S295-S295.	0.9	2
332	Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1350-1356.	1.7	2
333	Genomic epidemiology and antibiotic susceptibility profiling of uropathogenic <i>Escherichia coli</i> among children in the United States. <i>MSphere</i> , 2023, 8, .	3.1	2
334	Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. <i>Clinical Infectious Diseases</i> , 2023, 77, S305-S313.	5.7	2
335	Study of melting transition on biphenyl by Raman scattering. <i>AIP Advances</i> , 2019, 9, 095049.	1.3	1
336	485. Clinical and Molecular Epidemiology of Carbapenem Non-susceptible <i>Citrobacter</i> sp.. <i>Open Forum Infectious Diseases</i> , 2019, 6, S237-S238.	0.9	1
337	Extensively drug-resistant IMP-16-producing <i>Pseudomonas monteilii</i> isolated from cerebrospinal fluid. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104658.	2.3	1
338	Coexistence of Hypertension and Diabetes Mellitus in Elderly Population of Arar City, Northern Saudi Arabia. <i>The Egyptian Journal of Hospital Medicine</i> , 2017, 69, 3154-3159.	0.1	1
339	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical Isolates. <i>Phage</i> , 2022, 3, 50-58.	2.3	1
340	Dissecting the clonality of I1 plasmids using ORF-based binarized structure network analysis of plasmids (OSNap). <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 473-479.	1.7	1
341	An early return-to-work program for COVID-19 close contacts in healthcare during the Omicron wave in Japan. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 102-104.	1.7	1
342	Comparison of Biological Activities of BafA Family Autotransporters within <i>Bartonella</i> Species Derived from Cats and Rodents. <i>Infection and Immunity</i> , 2023, 91, .	2.4	1

#	ARTICLE	IF	CITATIONS
343	Daily fosfomycin versus levofloxacin for complicated urinary tract infections. <i>MBio</i> , 2023, 14, .	4.4	1
344	Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2024, 30, 219-227.	1.7	1
345	A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 1767.	4.5	1
346	Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185. <i>MBio</i> , 2024, 15, .	4.4	1
347	Clinical and genomic characteristics of IMP-producing <i>Enterobacter cloacae</i> complex and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2024, 68, .	3.4	1
348	Von B̈ı̇chern allgemein analytischen Inhaltes. <i>Analytical and Bioanalytical Chemistry</i> , 1903, 42, 519-522.	3.9	0
349	Characterization of the polarization mode dispersion of single mode fibre in KAT-7 telescope array network, South Africa. , 2013, , .		0
350	32: The Presence of an 11,111 m/z Peak in the Mass Spectrum of <i>Escherichia coli</i> Is Suggestive of <i>Klebsiella pneumoniae</i> Carbapenemase-Mediated Carbapenem Resistance. <i>American Journal of Clinical Pathology</i> , 2015, 143, A016-A016.	0.7	0
351	Salim Tamari and Issam Nassar , eds. <i>The Storyteller of Jerusalem: The Life and Times of Wasif Jawhariyyeh, 1904-1948</i> . Translated by Nada Elzeer , foreword by Rachel Beckles Willson . Northampton, MA: Olive Tree Press, 2014. 304 pages. Paper US\$25.00 ISBN 978-1566569255.. <i>Review of Middle East Studies</i> , 2016, 50, 128-132.	0.0	0
352	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in <i>Klebsiella pneumoniae</i> (CRaCKle). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
353	Reply to Iwata: Are all fosfomycins alike? Reply to author. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 725.	1.7	0
354	1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S356-S357.	0.9	0
355	2065. Whole Genome Sequencing for Antimicrobial Resistance Prediction in MRSA and VRE: A Real-world Application. <i>Open Forum Infectious Diseases</i> , 2018, 5, S603-S603.	0.9	0
356	Absence of fosfomycin resistance in gastrointestinal <i>Escherichia coli</i> following fosfomycin therapy. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 14, 109-110.	2.5	0
357	508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the Urinary Tract. <i>Open Forum Infectious Diseases</i> , 2019, 6, S246-S246.	0.9	0
358	622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS). <i>Open Forum Infectious Diseases</i> , 2019, 6, S289-S289.	0.9	0
359	The Elucidation of Pathogenicity of Carbapenemase-Producing <i>Klebsiella Pneumoniae</i> Pulmonary Infection Using Single Cell RNAseq. , 2019, , .		0
360	630. Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S292-S292.	0.9	0

#	ARTICLE	IF	CITATIONS
361	2282. Empiric Antimicrobial Therapy and Clinical Outcomes of Infections due to ESBL-producing <i>Klebsiella pneumoniae</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S781-S782.	0.9	0
362	605. Identification of a Novel CMY-Variant Enzyme in a Clinical <i>Escherichia coli</i> Strain with Treatment-Emergent Ceftazidime-â€“Avibactam Resistance. <i>Open Forum Infectious Diseases</i> , 2019, 6, S283-S283.	0.9	0
363	<i>Pseudomonas Aeruginosa</i> Protease and Elastase Activity Are Common in ICU Respiratory Isolates. , 2019, , .		0
364	Pathogenicity of <i>mcr-1</i> -positive <i>Escherichia coli</i> from human infections. <i>Lancet Microbe</i> , The, 2020, 1, e195.	6.7	0
365	Increased Alternative Complement Pathway Function Improves Survival During Critical Illness. , 2020, , .		0
366	<i>Pseudomonas Aeruginosa</i> Protease and Elastase Activity Are Associated with Increased 30-Day Mortality in ICU Patients. , 2020, , .		0
367	Global Spread of Multidrug-Resistant Gram-Negative Bacilli. , 0, , 213-222.		0
368	Risk factors for the development of infections associated with carbapenemase-producing Enterobacteriaceae among previously colonized patients: A retrospective cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1-4.	2.0	0
369	Title is missing!. , 0, , .		0
370	Comparison of three rapid diagnostic tests for bloodstream infections using Benefit-risk Evaluation Framework (BED-FRAME). <i>Journal of Clinical Microbiology</i> , 0, , .	4.4	0
371	In Vivo Evolution of a <i>Klebsiella pneumoniae</i> Capsule Defect With <i>wcaJ</i> Mutation Promotes Complement-Mediated Opsonophagocytosis During Recurrent Infection. <i>Journal of Infectious Diseases</i> , 0, , .	3.9	0
372	Differential <i>in vitro</i> susceptibility to ampicillin/ceftriaxone combination therapy among <i>Enterococcus faecalis</i> infective endocarditis clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2024, 79, 801-809.	3.2	0
373	Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2024, 63, 107119.	3.3	0
374	How Much More Efficient Are Adaptive Platform Trials Than Multiple Stand-Alone Trials? A Comprehensive Simulation Study for Streamlining Drug Development During a Pandemic. <i>Clinical Pharmacology and Therapeutics</i> , 2024, 115, 1372-1382.	4.9	0
375	The relationship between self-stigma and quality of life in long-term hospitalized patients with schizophrenia: a cross-sectional study. <i>Frontiers in Psychiatry</i> , 0, 15, .	2.7	0
376	Clinical characteristics and genome epidemiology of <i>Stenotrophomonas maltophilia</i> in Japan. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.2	0
377	Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.2	0
378	Paediatric very rare tumours registration and management in European countries with low health expenditure average rates. <i>Clinical and Translational Oncology</i> , 0, , .	2.5	0

#	ARTICLE	IF	CITATIONS
379	Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infections. JAC-Antimicrobial Resistance, 2024, 6, .	2.1	0
380	Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	0
381	Characterization of <i>Pseudomonas aeruginosa</i> from subjects with diffuse panbronchiolitis. Microbiology Spectrum, 0, , .	3.0	0